Back

Efficacy and safety of oral anticoagulant versus antiplatelet therapy for secondary prevention of cardiovascular disease in patients without atrial fibrillation

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Antiplatelet therapy Anticoagulants ESC Premium Access ESC Congress 2019

About the speaker

Photo
Assistant Professor Fabrizio Ricci

G. d Annunzio University of Chieti-Pescara, Chieti (Italy)

4 More presentations in this session

Presentation thumbnail
A randomized, pharmacodynamic comparison of low dose ticagrelor (60mg bid) to low dose prasugrel (5mg od) in patients with prior myocardial infarction: the ALTIC-2 study
Doctor I. Lianos (London, GB)
Abstract Slides
Presentation thumbnail
Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis
Doctor D. Errigo (Turin, IT)
Abstract Slides
Presentation thumbnail
Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischaemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients
Doctor J. Li (Beijing, CN)
Abstract
Presentation thumbnail
Bleedings during antithrombotic therapy: a blessing in disguise
Doctor D. Cosmi (Perugia, IT)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Antiplatelet therapy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus: a meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources